Ad hoc announcement pursuant to Art. 53LR
Pratteln, Swiss, June 32022 –Santhera Pharmaceuticals (SIX: SANN) has updated company calendar. The company will be publish his 2021 Aannual Rreport on June ten, 2022 and hold its annual general meeting on June 302022.
SIX Exchange Regulation has authorized Santhera to publish its annual report for the year ended December 31, 2021, on June 10, 2022. Following the success of Santhera’s financing announced on June 2, 2022, Santhera is in the process of finalizing the 2021 annual report .
In addition, SIX Exchange Regulation has approved the listing of 15,500,000 existing treasury shares of Santhera effective Tuesday, June 7, 2022.
SIX EXCHANGE REGULATION DECISION
In order to allow the finalization of the annual report, SIX Exchange Regulation has granted an extension for the publication of the 2021 annual report. In accordance with the requirements of SIX Exchange Regulation, Santhera reproduces here the following excerpt from the decision of SIX Exchange Regulation German original):
The exemption from the obligations to maintain listing and therefore the postponement of the publication of the annual report for the year 2021 as well as the filing of this report with SIX Exchange Regulation Ltd before June 102022 at the latest is approved subject to the following provision (lit. a) and conditions (lit. b):
a. SIX Exchange Regulation NV reserves the right to suspend trading in the securities of Santhera Pharmaceuticals Holding NV for a certain period if it does not publish its annual report for the year 2021 in accordance with the provisions on ad hoc publicity (Art. 53 Regulation of listing in conjunction with the Directive on event advertising) and submit it to SIX Exchange Regulation SA before 11:59 p.m. on Friday, June 102022, at the latest.
b. Santhera must issue a press release regarding this decision in accordance with the provisions on event advertising (Art. 53 Listing Rules in conjunction with the Event Advertising Directive) in 23:59 Friday, June 3, 2022 at the latest. Such a press release
- must include the full text of Clause I of this decision in a prominent place;
- must state the reasons for Again adjourn the publication and filing of the annual report for the year 2021.
June 2, 2022 Press release “Santhera Announces Improved Liquidity Position”, accessible here.
June 10, 2022 Publication of the 2021 annual report and notice of the 2022 general meeting
June 30, 2022 Annual General Meeting
Santhera Pharmaceuticals (SIX:SANN) is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative medicines for rare neuromuscular and pulmonary diseases with high unmet medical need. Santhera holds an exclusive license for all indications worldwide for vamorolone, a dissociative steroid with a novel mode of action, which has been studied in a pivotal study in patients with DMD as an alternative to standard corticosteroids. The company expects to complete the continued submission of its approval dossier for vamorolone to the U.S. FDA in June 2022. The clinical-stage pipeline also includes lonodelestat to treat cystic fibrosis (CF) and other lung diseases neutrophils. Santhera has licensed the rights to its first approved product, Raxone® (idebenone), outside of North America and France for the treatment of Leber’s Hereditary Optic Neuropathy (LHON) to the Chiesi Group. For more information, please visit www.santhera.com.
raxon® is a registered trademark of Santhera Pharmaceuticals.
Disclaimer / Forward-Looking Statements
This communication does not constitute an offer or an invitation to subscribe or purchase securities of Santhera Pharmaceuticals Holding AG. This publication may contain certain forward-looking statements regarding the Company and its business. These statements involve certain risks, uncertainties and other factors that could cause the actual results, financial condition, performance or achievements of the Company to be materially different from those expressed or implied by these statements. Readers should therefore not place undue reliance on such statements, particularly in connection with any contract or investment decision. The Company disclaims any obligation to update these forward-looking statements.
# # #
2022 06 03_SANN-CorpCal_e_final